Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 2, 2005, Pages 101-107

  Goldberg, Jenna ^a   Jacobsohn, David A ^b   Zahurak, Marianna L ^a   Vogelsang, Georgia B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Diarrhea; Graft versus host disease; Preparative regimen

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; METHYLPREDNISOLONE; THALIDOMIDE;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; ENTEROPATHY; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEALTH CARE FACILITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE INFECTION; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIBLING; STATISTICAL SIGNIFICANCE; UNITED STATES; WHOLE BODY RADIATION;

EID: 13244268242     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.10.007     Document Type: Article

References (24)

1. D.L. Porter M.S. Roth C. Cariole et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia N Engl J Med 330 1994 100-106
2. M.T. Lin B. Storer P.J. Martin et al. Relation of an interleukin-10 promotor polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation N Engl J Med 349 2003 2201-2210
3. E. Holler H.J. Kolb J. Mittermuller et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor-α release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα Blood 86 1995 890-899
4. F.P. Nestel K.S. Price T.A. Seemayer W.S. Lapp et al. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft-versus-host disease J Exp Med 175 1992 405-413
5. J.H. Antin H.J. Weinstein E.C. Guinan et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease Blood 85 1994 1342-1348
6. E. Holler H.J. Kolb J. Kempeni et al. Increased serum levels of tumor necrosis factor-α precede major complications of bone marrow transplantation Blood 75 1990 1011-1016
7. G.R. Hill J.M. Crawford K.R. Cooke Y.S. Brinson L. Pan J.L. Ferrara Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines Blood 90 1997 3204-3213
8. G.R. Hill J.L.M. Ferrara The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation Blood 95 2000 2754-2759
9. R. Storb R.L. Prentice C.D. Buckner et al. Graft versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: Beneficial effect of a protective environment N Engl J Med 308 1983 302-307
10. D.W. Beelen E. Haralambie H. Brandt et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation Blood 80 1992 2668-2676
11. K.R. Cooke G.R. Hill J.M. Crawford et al. Tumor necrosis factor-α production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease J Clin Invest 102 1998 1882-1891
12. J.E. Wagner A.D. Donnenberg S.J. Noga et al. Separation of rat bone marrow cells by counterflow centrifugal elutriation: A model for studying the effects of lymphocyte depletion Exp Hematol 3 1988 206-212
13. D. Przepiorka D. Weisdorf P. Martin et al. 1994 Consensus Conference on Acute GVHD Grading Bone Marrow Transplant 6 1995 825-828
14. D.R. Cox The Analysis of Binary Data 1970 Methuen London
15. SAS Institute Inc SAS User's Guide: Statistics, Version 5 Edition 1985 SAS Institute Inc Cary, NC
16. Statistics and Epidemiology Research Corp EGRET Users' Manual 1988 Statistics and Epidemiology Research Corp Seattle, WA
17. K.R. Cooke A. Gerbitz J.M. Crawford et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation J Clin Invest 107 2001 1581-1589
18. M. Remberger O. Ringden M. Markling TNF-α levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD Bone Marrow Transplant 15 1995 99-104
19. D.H. Fowler J. Foley J. Whit-Shan Hou et al. Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor α with severe gut graft-versus-host disease Clin Gastroenterol Hepatol 2 2004 237-245
20. P. Herve M. Flesch P. Tiberghien et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of a refractory severe acute graft-versus-host disease Blood 12 1992 3362-3368
21. G.R. Hill T. Teshima A. Gerbitz et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia J Clin Invest 4 1999 459-467
22. P. Rutgeerts G. D'Haens S. Targan et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Gastroenterology 117 1999 761-769
23. D.H. Present P. Rutgeerts S. Targan et al. Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398-1405
24. O. Ringden M. Labopin N. Gorin et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol 27 2004 416-423